Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsJeffrey Topal, MD
Associate Clinical ProfessorAbout
Research
Publications
2025
A mixed-methods study assessing the performance of a clinical decision support tool for Clostridioides difficile testing for patients receiving laxatives
Peaper D, Rathod S, Sussman L, Azar M, Murdzek C, Roberts S, Tichy E, Topal J, Kashyap N, McManus D, Martinello R. A mixed-methods study assessing the performance of a clinical decision support tool for Clostridioides difficile testing for patients receiving laxatives. Infection Control And Hospital Epidemiology 2025, 46: 497-503. PMID: 40079209, PMCID: PMC12034449, DOI: 10.1017/ice.2025.30.Peer-Reviewed Original ResearchClinical decision supportAdvanced practice providersClinical decision support alertsClinical decision support toolMixed-methods studyPractice providersClinician interactionClinician concernsPhysician's instructionsTest orderingAttending physiciansMixed-methodsDoses of laxativesPatient riskLaxative useClinicians' rationaleCliniciansDecision support toolHospitalized patientsStudy periodDecision supportAttendanceCase seriesAntibiotic exposureResidents
2024
Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections
Shah S, Adams K, Clarke L, Ludwig J, McManus D, Nguyen M, Topal J, Shields R. Clinical outcomes of a twice-daily metronidazole dosing strategy for Bacteroides spp. bloodstream infections. International Journal Of Antimicrobial Agents 2024, 65: 107403. PMID: 39667533, DOI: 10.1016/j.ijantimicag.2024.107403.Peer-Reviewed Original ResearchClinical failureDosing strategiesClinical outcomesIncreased risk of clinical failureRetrospective chart review of adult patientsChart review of adult patientsReview of adult patientsRate of clinical failureClinical outcomes of patientsRisk of clinical failureAssociated with worse outcomesOutcomes of patientsRetrospective chart reviewBloodstream infectionsMetronidazole doseAdult patientsWorse outcomesIncreased riskMetronidazolePatientsInclusion criteriaBacteroides sppBacteremiaDoseMortalityImproving cefazolin administration for surgical prophylaxis in reported penicillin allergy: A retrospective study of a health system intervention
Belmont A, Son M, Hyman J, You L, Su C, Kashyap N, Topal J, McManus D, Martinello R, Kwah J. Improving cefazolin administration for surgical prophylaxis in reported penicillin allergy: A retrospective study of a health system intervention. Journal Of Allergy And Clinical Immunology Global 2024, 4: 100377. PMID: 39830990, PMCID: PMC11742594, DOI: 10.1016/j.jacig.2024.100377.Peer-Reviewed Original ResearchPenicillin allergy labelHospital-wide guidelinesSurgical site infectionAllergy labelsSurgical patientsSevere allergic reactionsSurgical prophylaxisSite infectionAssociated with increased rates of surgical site infectionRate of surgical site infectionMulti-drug resistant infectionsAllergic reactionsPrevent surgical site infectionsFirst-line antibioticsFirst-line prophylaxisAdministration of cefazolinAssociated with increased ratesRetrospective cohort studyGuideline-directed therapyAdult surgical patientsPre-intervention groupPost-intervention groupPenicillin allergyPerioperative outcomesCefazolin administrationClinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah S, Clarke L, Davis M, Topal J, Shields R. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal Of Antimicrobial Chemotherapy 2024, 79: 2017-2021. PMID: 38958234, PMCID: PMC12102595, DOI: 10.1093/jac/dkae205.Peer-Reviewed Original ResearchPseudomonas endocarditisFirst-lineClinical outcomesShorter time to treatment initiationFactors associated with treatment failureInvestigate clinical outcomes of patientsClinical outcomes of patientsTime to treatment initiationRate of adverse effectsProsthetic valve endocarditisFirst-line therapyOrgan transplant recipientsOutcomes of patientsInvestigate clinical outcomesIntracardiac complicationsDuke criteriaMicrobiological failureDrug discontinuationValve endocarditisCombination therapyTreatment failureTransplant recipientsDay mortalityInitial treatmentClinical benefitNocardiosis in Kidney Transplant Recipients and Possible Association With Decreased Utilization of Trimethoprim/Sulfamethoxazole During COVID-19
Marvin J, McSweeney T, Cohen E, Davis M, Belfield K, Do V, Virmani S, McManus D, Tirmizi S, Topal J. Nocardiosis in Kidney Transplant Recipients and Possible Association With Decreased Utilization of Trimethoprim/Sulfamethoxazole During COVID-19. Transplantation 2024, 108: e150-e151. PMID: 38917242, DOI: 10.1097/tp.0000000000004974.Peer-Reviewed Original ResearchClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients
2023
2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed?
Perreault S, Schiffer M, Roeder H, McManus D, Topal J. 2737. Real World Evaluation of Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant (aHSCT) Patients, Is Routine Antifungal Prophylaxis Needed? Open Forum Infectious Diseases 2023, 10: ofad500.2348. PMCID: PMC10678736, DOI: 10.1093/ofid/ofad500.2348.Peer-Reviewed Original ResearchInvasive fungal infectionsBreakthrough invasive fungal infectionsAntifungal prophylaxisFluconazole prophylaxisRisk factorsDay 75Conditioning regimenRisk patientsLower incidenceAllogeneic hematopoietic stem cell transplant patientsHistory of IFIRate of IFIHematopoietic stem cell transplant patientsHigh-intensity conditioning regimensStem cell transplant patientsFungal infectionsAnti-mold prophylaxisHigh-dose steroidsRoutine antifungal prophylaxisTacrolimus/sirolimusIntensity conditioning regimensHigh-risk patientsLow-risk patientsCell transplant patientsBreakthrough fungal infections